Everything below concerns eumelanin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-22. Numbers and descriptions here follow the published literature rather than marketing material.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Marine radio – medium-range transceivers on ships, used for ship-to-ship, ship-to-air, and ship-to-shore communication with harbormasters They use FM channels between 156 and 174 MHz in the VHF band with up to 25 watts power, giving them a range of about 60 miles (97 km). Some channels are half-duplex and some are full-duplex, to be compatible with the telephone network, to allow users to make telephone calls through a marine operator. Amateur radio – long-range half-duplex two-way radio used by hobbyists for non-commercial purposes: recreational radio contacts with other amateurs, volunteer emergency communication during disasters, contests, and experimentation. Radio amateurs must hold an amateur radio license and are given a unique callsign that must be used as an identifier in transmissions. Amateur radio is restricted to small frequency bands, the amateur radio bands, spaced throughout the radio spectrum starting at 136 kHz. Within these bands, amateurs are allowed the freedom to transmit on any frequency using a wide variety of voice modulation methods, along with other forms of communication, such as slow-scan television (SSTV), and radioteletype (RTTY). Additionally, amateurs are among the only radio operators still using Morse code radiotelegraphy. Scanner - a receiver that continuously monitors multiple frequencies or radio channels by stepping through the channels repeatedly, listening briefly to each channel for a transmission. When a transmitter is found the receiver stops at that channel.
== Diving spread == The diving spread is a commercial diving term for the topside dive site infrastructure supporting the diving operations for a diving project. The diving contractor provides the diving and support equipment and sets it up on site, usually at a place provided for the purpose by the client, or on a diving support vessel. Two types of diving spread are in common use: Air spreads for surface oriented diving operations, where the divers are deployed from normal atmospheric pressure, and decompressed back to atmospheric pressure at the end of the dive, either in-water, or in a chamber for surface decompression, using compressed air as the primary breathing gas, and saturation spreads, where divers are deployed under pressure from the saturation accommodation via a closed diving bell to the underwater worksite, and returned under pressure in the bell to the saturation accommodation system, usually breathing a helium based gas mixture. At the end of their contract the divers are decompressed to surface pressure. The process of selecting, transporting, setting up and testing the equipment is the mobilisation stage of the project, and the demobilisation involves dismantling, transportation and return to storage of the spread components. Surface oriented mixed gas diving spreads may also be used, but are less common, and are likely to be associated with projects which are too deep for air but require only a short working time at depth.
The behavior of NAPLs in the subsurface is guided by both the composition of the subsurface material and the various properties of the NAPLs. The subsurface can be categorized into two primary zones: the unsaturated (vadose) zone, which includes small grains or particles surrounded by a thin film of water; and the saturated (phreatic) zone, which contains important storages of groundwater called aquifers. NAPLs are point-source pollutants, and they can be released from a variety of sources, including, but not limited to, improper chemical disposal, leaking underground storage tanks, septic tank effluent, and percolation from spills or landfills. Under high precipitation conditions, liquid will infiltrate the unsaturated zone; if there is enough volume of liquid, it will then percolate into the saturated zone. The porosity of the subsurface environment will determine the quantity that manages to enter the saturated zone.
Sources: en.wikipedia.org
Carrier ionophores that bind to a particular ion and shield its charge from the surrounding environment. This makes it easier for the ion to pass through the hydrophobic interior of the lipid membrane. However, these ionophores become unable to transport ions under very low temperatures. An example of a carrier ionophore is valinomycin, a molecule that transports a single potassium cation. Carrier ionophores may be proteins or other molecules. Channel formers that introduce a hydrophilic pore into the membrane, allowing ions to pass through without coming into contact with the membrane's hydrophobic interior. Channel forming ionophores are usually large proteins. This type of ionophores can maintain their ability to transfer ions at low temperatures, unlike carrier ionophores. Examples of channel-forming ionophores are gramicidin A and nystatin. Ionophores that transport hydrogen ions (H+, i.e. protons) across the cell membrane are called protonophores. Iron ionophores and chelating agents are collectively called siderophores.
=== International organizations === United Nations: UN Secretary General Antonio Guterres said Gaza was an integral part of a future Palestinian state. Amnesty International's Agnès Callamard condemned Trump's plan to take over Gaza and forcibly relocate Palestinians, calling it "outrageous and shameful." She said it would be a war crime and urged the global community to reject it and uphold Palestinian rights. International Coordination of Revolutionary Parties and Organizations: The ICOR released a statement condemning Trump's Gaza plan saying that it would be tantamount to a new Nakba. Holy See: The Catholic Patriarch of Jerusalem, Pierbattista Pizzaballa, on July 21, 2025, stated that the majority in Gaza will remain there: “First of all, they don’t know where to go, but they also don’t want to leave, because their roots are there, their home is there—or rather, they had their home there—and they want to rebuild it there. The Pope has been very clear on this: no population transfers; there will be no 'rivieras' in Gaza”.
=== "In the Hepatitis B Camp" === "In the Hepatitis B Camp" is a popular website for hepatitis B carriers' human rights in China. Its online forum is the world's biggest such forum with over 300,000 members. The website was first shut down by the Chinese government in November 2007. Lu Jun, the head of the rights group, managed to reopen the website by moving it to an overseas server, but the authorities in May 2008 began blocking access to the website within China, only 10 days after government officials participated in an event for World Hepatitis Day at the Great Wall of China. An official had told the head of the rights group, Lu Jun, at the time that the closure was due to the Beijing Olympic Games.
Physical pharmacy is the branch of pharmacy that concentrates on the applications of physics and chemistry to the study of pharmacy. In other words, it is the study of the effects that dosage forms have on their environment by addressing issues at the molecular level. It emphasis on the physical characteristics and actions of the drug delivery system before the same is given to the patient. It forms the basis for design, manufacture, and distribution of drug products and serves as the foundation for the stable and proper use of medical drugs. It covers areas such as solubility, pharmacokinetics and drug delivery. Physical pharmacy serves as principles that guide the pharmaceutical developments. It also serves as a basis for the understanding of drug absorptions, distributions, metabolism, and eliminations that happen during the course of drug treatment.
Sources: en.wikipedia.org
=== The catalytic domain === X-ray crystallographic structures of several MMP catalytic domains have shown that this domain is an oblate sphere measuring 35 x 30 x 30 Å (3.5 × 3 x 3 nm). The active site is a 20 Å (2 nm) groove that runs across the catalytic domain. In the part of the catalytic domain forming the active site there is a catalytically important Zn2+ ion, which is bound by three histidine residues found in the conserved sequence HExxHxxGxxH. Hence, this sequence is a zinc-binding motif. The gelatinases, such as MMP-2, incorporate Fibronectin type II modules inserted immediately before in the zinc-binding motif in the catalytic domain.
== Signs and symptoms == These descriptions refer to 'classic' Alport syndrome, which usually causes significant disease from young adult or late childhood life. Some individuals, usually with milder mutations or 'carrier' status, develop disease later, or show only some of the features of classic disease.
Anchoring fibrils (composed largely of type VII collagen) extend from the basal lamina of epithelial cells and attach to the lamina reticularis (also known as the reticular lamina) by wrapping around the reticular fiber (collagen III) bundles. The basal lamina and lamina reticularis together make up the basement membrane. Anchoring fibrils are essential to the functional integrity of the dermoepidermal junction.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.